Anti‑inflammatory effects of the NF‑κB inhibitor dehydroxymethylepoxyquinomicin on ARPE‑19 cells

Ando,Yoshimasa; Sato,Yasuhiko; Kudo,Akihiko; Watanabe,Takayo; Hirakata,Akito; Okada,Annabelle A.; Umezawa,Kazuo; Keino,Hiroshi

doi:10.3892/mmr.2020.11115

Anti‑inflammatory effects of the NF‑κB inhibitor dehydroxymethylepoxyquinomicin on ARPE‑19 cells

Authors:
- Yoshimasa Ando
- Yasuhiko Sato
- Akihiko Kudo
- Takayo Watanabe
- Akito Hirakata
- Annabelle A. Okada
- Kazuo Umezawa
- Hiroshi Keino
View Affiliations

Affiliations: Department of Ophthalmology, Kyorin University School of Medicine, Tokyo 181‑8611, Japan, Division of Radioisotope Research, Kyorin University School of Medicine, Tokyo 181‑8611, Japan, Department of Anatomy, Kyorin University School of Medicine, Tokyo 181‑8611, Japan, Department of Molecular Target Medicine Screening, Aichi Medical University, Nagakute, Aichi 480‑1195, Japan
Published online on: May 4, 2020 https://doi.org/10.3892/mmr.2020.11115
Pages: 582-590

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The retinal pigment epithelium (RPE) is a polarized, monolayer of pigmented cells that forms the outer retinal layer. A key function of the RPE is to maintain the integrity of the photoreceptors mainly via phagocytosis and recycling of the digested photoreceptor outer segments. Moreover, RPE cells are a major source of inflammatory cytokines and chemokines, which play important roles in the activation of other immune cells under inflammatory conditions in the posterior segment of the eye. Dehydroxymethylepoxyquinomicin (DHMEQ) is a NF‑κB inhibitor and its structure is related to that of epoxyquinomicin C, which is an antibiotic. The present study evaluated the anti‑inflammatory effects of DHMEQ on a human retinal pigment epithelial cell line (ARPE‑19). It was revealed that high concentrations of DHMEQ (100 µg/ml) induced apoptosis and necrosis of tumor necrosis factor (TNF)‑α‑stimulated ARPE‑19 cells. Furthermore, the percentage of intercellular adhesion molecule 1 (ICAM‑1)‑positive TNF‑α‑stimulated cells was significantly reduced in the presence of DHMEQ (10 µg/ml), as determined by flow cytometry. It was also demonstrated that DHMEQ exposure significantly decreased the levels of interleukin (IL)‑8 and monocyte chemoattractant protein‑1 (MCP‑1) in the supernatant of cultured ARPE‑19 cells as determined by ELISA. Moreover, the protein expression levels of IL‑8 and MCP‑1 were significantly reduced in ARPE‑19 cells exposed to DHMEQ compared with cells exposed to dexamethasone. PCR array analysis revealed that DHMEQ reduced the expression levels of MCP‑1, ICAM‑1, IL‑6, Toll‑like receptor (TLR)2, TLR3 and TLR4. Therefore, the present results indicated that DHMEQ has anti‑inflammatory effects on TNF‑α‑stimulated ARPE‑19 cells. Thus, DHMEQ may have therapeutic potential for TNF‑α‑mediated inflammatory disorders of the eye.

View Figures

View References

1	Holtkamp GM, Kijlstra A, Peek R and de Vos AF: Retinal pigment epithelium-immune system interactions: Cytokine production and cytokine-induced changes. Prog Retin Eye Res. 20:29–48. 2001. View Article : Google Scholar : PubMed/NCBI
2	Momma Y, Nagineni CN, Chin MS, Srinivasan K, Detrick B and Hooks JJ: Differential expression of chemokines by human retinal pigment epithelial cells infected with cytomegalovirus. Invest Ophthalmol Vis Sci. 44:2026–2033. 2003. View Article : Google Scholar : PubMed/NCBI
3	Elner SG, Delmonte D, Bian ZM, Lukacs NW and Elner VM: Differential expression of retinal pigment epithelium (RPE) IP-10 and interleukin-8. Exp Eye Res. 83:374–379. 2006. View Article : Google Scholar : PubMed/NCBI
4	Dick AD: Doyne lecture 2016: Intraocular health and the many faces of inflammation. Eye (Lond). 31:87–96. 2017. View Article : Google Scholar : PubMed/NCBI
5	Sugita S, Kawazoe Y, Imai A, Yamada Y, Horie S and Mochizuki M: Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behcet's disease. Arthritis Res Ther. 14:R992012. View Article : Google Scholar : PubMed/NCBI
6	Okada AA, Goto H, Ohno S and Mochizuki M; Ocular Behçet's Disease Research Group Of Japan, : Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol. 130:592–598. 2012. View Article : Google Scholar : PubMed/NCBI
7	Takeuchi M, Kezuka T, Sugita S, Keino H, Namba K, Kaburaki T, Maruyama K, Nakai K, Hijioka K, Shibuya E, et al: Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behcet's disease: A multicenter study. Ophthalmology. 121:1877–1884. 2014. View Article : Google Scholar : PubMed/NCBI
8	Jaffe GJ, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D, et al: Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 375:932–943. 2016. View Article : Google Scholar : PubMed/NCBI
9	Brenner D, Blaser H and Mak TW: Regulation of tumour necrosis factor signalling: Live or let die. Nat Rev Immunol. 15:362–374. 2015. View Article : Google Scholar : PubMed/NCBI
10	Hayden MS and Ghosh S: NF-kB in immunobiology. Cell Res. 21:223–244. 2011. View Article : Google Scholar : PubMed/NCBI
11	Okamoto H, Cujec TP, Yamanaka H and Kamatani N: Molecular aspects of rheumatoid arthritis: Role of transcription factors. FEBS J. 275:4463–4470. 2008. View Article : Google Scholar : PubMed/NCBI
12	Kawai T and Akira S: Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med. 13:460–469. 2007. View Article : Google Scholar : PubMed/NCBI
13	Wu J, Ding J, Yang J, Guo X and Zheng Y: MicroRNA roles in the nuclear factor kappa B signaling pathway in cancer. Front Immunol. 9:5462018. View Article : Google Scholar : PubMed/NCBI
14	Ariga A, Namekawa J, Matsumoto N, Inoue J and Umezawa K: Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem. 277:24625–24630. 2002. View Article : Google Scholar : PubMed/NCBI
15	Umezawa K: Inhibition of tumor growth by NF-kappaB inhibitors. Cancer Sci. 97:990–995. 2006. View Article : Google Scholar : PubMed/NCBI
16	Umezawa K and Chaicharoenpong C: Molecular design and biological activities of NF-kappaB inhibitors. Mol Cells. 14:163–167. 2002.PubMed/NCBI
17	Yamamoto M, Horie R, Takeiri M, Kozawa I and Umezawa K: Inactivation of NF-kappaB components by covalent binding of (−)-dehydroxymethylepoxyquinomicin to specific cysteine residues. J Med Chem. 51:5780–5788. 2008. View Article : Google Scholar : PubMed/NCBI
18	Lin Y, Ukaji T, Koide N and Umezawa K: Inhibition of late and early phases of cancer metastasis by the NF-kB inhibitor DHMEQ derived from microbial bioactive metabolite epoxyquinomicin: A review. Int J Mol Sci. 19:E7292018. View Article : Google Scholar : PubMed/NCBI
19	Juel HB, Faber C, Udsen MS, Folkersen L and Nissen MH: Chemokine expression in retinal pigment epithelial ARPE-19 cells in response to coculture with activated T cells. Invest Ophthalmol Vis Sci. 53:8472–8480. 2012. View Article : Google Scholar : PubMed/NCBI
20	Zanon Cde F, Sonehara NM, Girol AP, Gil CD and Oliani SM: Protective effects of the galectin-1 protein on in vivo and in vitro models of ocular inflammation. Mol Vis. 21:1036–1050. 2015.PubMed/NCBI
21	Yang PM, Wu ZZ, Zhang YQ and Wung BS: Lycopen inhibits ICAM-1 expression and NF-kB activation by Nrf2-regulated cell redox state in human retinal pigment epithelial cells. Life Sci. 155:94–101. 2016. View Article : Google Scholar : PubMed/NCBI
22	Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F and Vandesompele J: A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 10:R642009. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Chen YH, Chen CL, Liang CM, Liang JB, Tai MC, Chang YH, Lu DW and Chen JT: Silibinin inhibits ICAM-1 expression via regulation of N-linked and O-linked glycosylation in ARPE-19 cells. Biomed Res Int. 2014:7013952014.PubMed/NCBI
25	Elner VM, Burnstine MA, Strieter RM, Kunkel SL and Elner SG: Cell-associated human retinal pigment epithelium interleukin-8 and monocyte chemotactic protein-1: Immunochemical and in-situ hybridization analyses. Exp Eye Res. 65:781–789. 1997. View Article : Google Scholar : PubMed/NCBI
26	Nagai N, Izumi-Nagai K, Oike Y, Koto T, Satofuka S, Ozawa Y, Yamashiro K, Inoue M, Tsubota K, Umezawa K and Ishida S: Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. Invest Ophthalmol Vis Sci. 48:4342–4350. 2007. View Article : Google Scholar : PubMed/NCBI
27	Chen JT, Liang JB, Chou CL, Chien MW, Shyu RC, Chou PI and Lu DW: Glucosamine sulfate inhibits TNF-alpha and IFN-gamma-induced production of ICAM-1 in human retinal pigment epithelial cells in vitro. Invest Ophthalmol Vis Sci. 47:664–672. 2006. View Article : Google Scholar : PubMed/NCBI
28	Chen JT, Chen PL, Chang YH, Chien MW, Chen YH and Lu DW: Glucosamine sulfate inhibits leukocyte adhesion in response to cytokine stimulation of retinal pigment epithelial cells in vitro. Exp Eye Res. 83:1052–1062. 2006. View Article : Google Scholar : PubMed/NCBI
29	Whitcup SM, Chan CC, Li Q and Nussenblatt RB: Expression of cell adhesion molecules in posterior uveitis. Arch Ophthalmol. 110:662–666. 1992. View Article : Google Scholar : PubMed/NCBI
30	Whitcup SM, DeBarge LR, Caspi RR, Harning R, Nussenblatt RB and Chan CC: Monoclonal antibodies against ICAM-1 (CD54) and LFA-1 (CD11a/CD18) inhibit experimental autoimmune uveitis. Clin Immunol Immunopathol. 67:143–150. 1993. View Article : Google Scholar : PubMed/NCBI
31	Uchio E, Kijima M, Tanaka S and Ohno S: Suppression of experimental uveitis with monoclonal antibodies to ICAM-1 and LFA-1. Invest Ophthalmol Vis Sci. 35:2626–2631. 1994.PubMed/NCBI
32	Crane IJ, McKillop-Smith S, Wallace CA, Lamont GR and Forrester JV: Expression of the chemokines MIP-1alpha, MCP-1, and RANTES in experimental autoimmune uveitis. Invest Ophthalmol Vis Sci. 42:1547–1552. 2001.PubMed/NCBI
33	Foxman EF, Zhang M, Hurst SD, Muchamuel T, Shen D, Wawrousek EF, Chan CC and Gery I: Inflammatory mediators in uveitis: Differential induction of cytokines and chemokines in Th1- versus Th2-mediated ocular inflammation. J Immunol. 168:2483–2492. 2002. View Article : Google Scholar : PubMed/NCBI
34	Keino H, Takeuchi M, Kezuka T, Yamakawa N, Tsukahara R and Usui M: Chemokine and chemokine receptor expression during experimental autoimmune uveoretinitis in mice. Graefes Arch Clin Exp Ophthalmol. 241:111–115. 2003. View Article : Google Scholar : PubMed/NCBI
35	Wakamatsu K, Nanki T, Miyasaka N, Umezawa K and Kubota T: Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells. Arthritis Res Ther. 7:R1348–R1359. 2005. View Article : Google Scholar : PubMed/NCBI
36	Iwata D, Kitaichi N, Miyazaki A, Iwabuchi K, Yoshida K, Namba K, Ozaki M, Ohno S, Umezawa K, Yamashita K, et al: Amelioration of experimental autoimmune uveoretinitis with nuclear factor-{kappa}B Inhibitor dehydroxy methyl epoxyquinomicin in mice. Invest Ophthalmol Vis Sci. 51:2077–2084. 2010. View Article : Google Scholar : PubMed/NCBI
37	Ando Y, Keino H, Kudo A, Hirakata A, Okada AA and Umezawa K: Anti-inflammatory effect of dehydroxymethylepoxyquinomicin, a nuclear factor-kB inhibitor, on endotoxin-induced uveitis in rats in vivo and in vitro. Ocul Immunol Inflamm. 28:240–248. 2020. View Article : Google Scholar : PubMed/NCBI
38	Gaudio PA: A review of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation. Ocul Immunol Inflamm. 12:169–192. 2004. View Article : Google Scholar : PubMed/NCBI
39	Van Bogaert T, De Bosscher K and Libert C: Crosstalk between TNF and glucocorticoid receptor signaling pathways. Cytokine Growth Factor Rev. 21:275–286. 2010. View Article : Google Scholar : PubMed/NCBI
40	Ukaji T and Umezawa K: Novel approaches to target NF-kB and other signaling pathways in cancer stem cells. Adv Biol Regul. 56:108–115. 2014. View Article : Google Scholar : PubMed/NCBI
41	de Castro Barbosa ML, da Conceicao RA, Fraga AGM, Camarinha BD, de Carvalho Silva GC, Lima AGF, Cardoso EA and de Oliveira Freitas Lione V: NF-kB signaling pathway inhibitors as anticancer drug candidates. Anticancer Agents Med Chem. 17:483–490. 2017. View Article : Google Scholar : PubMed/NCBI
42	Miyake A, Dewan MZ, Ishida T, Watanabe M, Honda M, Sata T, Yamamoto N, Umezawa K, Watanabe T and Horie R: Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ. Microbes Infect. 10:748–756. 2008. View Article : Google Scholar : PubMed/NCBI
43	Fukushima T, Kawaguchi M, Yorita K, Tanaka H, Takeshima H, Umezawa K and Kataoka H: Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-kB, on glioblastoma. Neuro Oncol. 14:19–28. 2012. View Article : Google Scholar : PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI